AstraZeneca loses appeal on Prilosec patents
16 June 2008
Eklavya Gupte, London
A Federal Court has ruled that US pharmaceutical company Mylan’s generic version of Prilosec does not infringe AstraZeneca’s patents
On Wednesday June 10 the US Court of Appeals for the Federal Circuit upheld the May 2007 District Court ruling that Mylan's 10mg and 20mg Omeprazole delayed-release capsules do not violate AstraZeneca’s patents for Prilosec.
Prilosec is used to treat heartburn, acid indigestion and intestinal ulcers. Mylan launched a generic version of the drug called Omeprazole on August 4 2003.
Mylan vice chairman and...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial